Revelation Biosciences Q1 net loss widens as expenses rise

Revelation Biosciences

07/05/2026 21:50

Overview

U.S. clinical-stage life sciences firm's Q1 net loss widened yr/yr

Operating expenses rose, driven by higher R&D and administrative costs

Company ended Q1 with increased cash, aided by warrant inducement proceeds

Outlook

Company expects current cash to fund operations through Q1 2027

Company focused on initiating pivotal clinical study for Gemini in acute kidney injury

Result Drivers

R&D SPENDING - Higher research and development costs contributed to increased operating expenses

ADMINISTRATIVE COSTS - General and administrative expenses rose yr/yr, adding to overall operating expenses

CLINICAL PROGRAM PROGRESS - Co cited regulatory agreement and preparations for pivotal Gemini study as key operational focus

Company press release: ID:nACSt31L1a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$2.71
Q1 Net Income
-$3 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Revelation Biosciences Inc is $53.00, about 5,096.1% above its May 6 closing price of $1.02

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)